Medical center DEA Medicals Ltd.

Research site

Bulgaria Ulitsa Georgi Izmirliev 8, 1404 Sofia, Bulgaria

4 trials recruiting
Cardiovascular disorder · Hypertension · Heart failure with preserved ejection fraction
Adult patients

About Specializations

Medical center DEA Medicals Ltd. in Sofia, Bulgaria specialises in clinical trials of conditions such as Cardiovascular disorder, Hypertension, Heart failure with preserved ejection fraction, Cardiac failure, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ulitsa Georgi Izmirliev 81404 SofiaBulgaria

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 4

More sites in Sofia Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

4 clinical trials

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites